Ipratropium / Albuterol: study card

Ipratropium / Albuterol — Anticholinergic + beta-2-adrenergic bronchodilator combination. Study the mechanism, listed uses and warnings from the US label on one sourced card.

Generic name: Ipratropium / Albuterol
Class: Anticholinergic + beta-2-adrenergic bronchodilator combination
Mechanism: Ipratropium blocks muscarinic acetylcholine receptors; albuterol stimulates beta2 receptors, raising cAMP and relaxing airway muscle.
Used for: COPD bronchospasm needing two bronchodilators
Common side effects: Lung disease; Pharyngitis; Chest pain; Bronchitis; Diarrhea
Warnings: Hypersensitivity to atropine or derivatives
Interactions: Other anticholinergic agents; Other sympathomimetic agents; Beta-blockers

Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.

Read the source label ↗

Label date: 20260818 · For learning, not clinical decisions. US label and brand information; always consult the current source.

Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.

Practice

Pronunciation

Ipratropium: i-pra-TROE-pee-um · Albuterol: al-BYOO-ter-ol

Pronunciation is shown for the US English generic name.

Body system

Respiratory · 19 Drug cards

Compare with related cards

Albuterol

Same body system: Respiratory

Mechanism: Activates beta-2 receptors on airway smooth muscle, raising cyclic AMP via adenylcyclase and relaxing bronchial smooth muscle.

On both cards: Common side effects — Pharyngitis · Interactions — Beta-blockers

Only on the Albuterol card: Used for — Bronchospasm treatment or prevention in reversible obstructive airway disease, aged 4 or older; Exercise-induced bronchospasm prevention, aged 4 or older · Common side effects — Headache; Tachycardia; Pain; Dizziness · Warnings — Paradoxical bronchospasm; Cardiovascular effects; Hypokalemia · Interactions — Non-potassium-sparing diuretics; MAO inhibitors, tricyclic antidepressants

Fluticasone Propionate / Salmeterol

Same body system: Respiratory

Mechanism: Fluticasone: synthetic corticosteroid with anti-inflammatory activity; salmeterol: long-acting beta2-agonist bronchodilator.

On both cards: Common side effects — Pharyngitis · Interactions — Beta-blockers

Only on the Fluticasone Propionate / Salmeterol card: Used for — Asthma maintenance from age 4 when an inhaled corticosteroid alone is inadequate or combined ICS/LABA therapy is warranted; COPD maintenance and exacerbation reduction with the specifically indicated DISKUS strength · Common side effects — Upper respiratory tract infection; Dysphonia; Oral candidiasis; Headache · Warnings — Not for acute bronchospasm; Pneumonia in COPD; Adrenal suppression / reduced bone density · Interactions — Strong CYP3A4 inhibitors; MAOIs / tricyclic antidepressants

An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.